相关实验视频
Updated: May 29, 2025

11:42
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
9.3K
代谢程序的表观遗传失调调节介于脂肉瘤细胞可塑性
Erica M Pimenta1,2,3,4, Amanda E Garza1,2, Sabrina Y Camp1,2
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
bioRxiv : the preprint server for biology
|February 3, 2025
概括
不分化脂肪瘤 (DDLPS) 显示出脂肪细胞分化的缺陷,原因是胰岛素样生长因子1 (IGF1) 途径功能障碍. 向IGF1受体 (IGF1R) 提供了一种潜在的治疗策略来治疗脂肪肉瘤.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症干细胞研究研究
背景情况:
- 瘤是一种罕见的结缔组织癌症,起源于介质干细胞 (MSC).
- 脂肉瘤 (LPS) 亚型,分化良好的 (WDLPS) 和分化不良的 (DDLPS),表现出不同的组织学和临床行为.
- 对于LPS亚型分化的分子驱动因素在很大程度上是未知的.
研究的目的:
- 为了阐明底层的分子路径,以及不分化的脂质瘤亚型.
- 为了识别导致脂肉瘤脱差的关键分子缺陷.
- 探索潜在的治疗瘤瘤的潜在治疗点.
主要方法:
- 单核多原子测序和人类脂肪肉瘤样本的空间概况.
- 试验室内刺激试验用于研究胰岛素样生长因子1 (IGF1) 途径的功能.
- 对脂肪细胞特异分化标记物的分析,包括PPARG2.
主要成果:
- 脂质肉瘤样本显示脂肪细胞特异化受损.
- 分离性脂肪瘤 (DDLPS) 的特征是失去IGF1信号传递和改变间酶体和GLP-1相关通路.
- 在DDLPS中,IGF1缺乏与较差的患者存活率和减少的PPARG2表达相关.
- 在DDLPS中的IGF1R上调表明对IGF1R向疗法的敏感性.
结论:
- 脂肪生成中的特定血统缺陷有助于脂质瘤的脱差.
- 功能失调的IGF1/PPARG2信号是DDLPS的一个关键特征.
- 针对IGF1R的抗体-药物结合体代表了治疗脂肉瘤治疗的有前途的治疗途径.
相关概念视频
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K

